Peptide Antagonists for Asthma Tight Junction Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for asthma do not effectively address the disruption of lung tight junctions, which contributes to allergen permeability and immune response, leading to asthma development, and there is a lack of specific treatments for reversing these effects.
Innovation Solution
The development of peptide antagonists that bind to the zonula occludens toxin receptor, specifically the amino acid sequence of SEQ ID NO: 15, to prevent the opening of tight junctions in the lung epithelium, thereby reducing allergen permeability and ameliorating asthma symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If glucocorticoids are used to suppress adaptive immune response, then inflammation is suppressed, but innate immune response including epithelial barrier function is not suppressed
Solution Approach 1:
The patent introduces peptide antagonists as intermediary substances that specifically bind to zonulin and ZOT toxins, preventing them from disrupting tight junctions. This mediator approach allows selective blockade of the harmful tight junction disruption pathway without affecting the broader anti-inflammatory actions of glucocorticoids, thereby preserving epithelial barrier function while maintaining inflammation suppression.
Solution Approach 2:
The patent changes the therapeutic parameter from general immune suppression to specific tight junction protection by using peptide antagonists that target the zonulin-ZOT-receptor axis. This parameter change enables selective intervention in the tight junction disruption mechanism while leaving other immune functions unaffected, resolving the contradiction between suppressing inflammation and maintaining barrier function.
2Object-affected harmful factors
If tight junctions are opened to allow antigen passage, then immune response is activated, but allergen permeability increases leading to asthma
Solution Approach 1:
The patent applies preliminary anti-action by administering peptide antagonists before allergens can disrupt tight junctions and trigger immune responses. The antagonists pre-block the zonulin-ZOT-receptor pathway, preventing the initial tight junction opening that would otherwise allow allergen permeation and subsequent immune activation, thereby stopping the harmful sequence before it begins.
Solution Approach 2:
The patent converts the harmful effect of tight junction opening into a beneficial protective mechanism by using peptide antagonists that exploit the same zonulin-ZOT-receptor pathway. Instead of allowing uncontrolled tight junction disruption, the antagonists bind to this pathway and convert it into a protective block, preventing allergen permeability while maintaining the ability to respond to genuine threats.
3Reliability
If peptide antagonists bind to ZOT receptor, then tight junction opening is inhibited, but binding affinity must be optimized
Solution Approach 1:
The patent applies parameter changes by systematically optimizing the peptide sequence parameters (amino acid composition, length, and structure) to achieve optimal binding affinity to the ZOT receptor. By varying these parameters, the invention identifies peptide sequences that maximize tight junction protection while minimizing off-target effects, resolving the need for precise manufacturing specifications.
Solution Approach 2:
The patent applies local quality by focusing optimization efforts on specific regions of the peptide molecule that are critical for receptor binding. Rather than optimizing the entire peptide uniformly, the invention identifies and optimizes key local sequences that interact with the ZOT receptor, thereby achieving high binding affinity and tight junction stability with more manageable manufacturing precision requirements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptide antagonists effectively maintain or decrease lung epithelium permeability, preventing or treating asthma by reducing transient disassembly of tight junctions, thereby reducing asthma severity and frequency of attacks.
Implementation Method 1
peptide antagonists that bind to the zonula occludens toxin receptor, specifically the amino acid sequence of SEQ ID NO: 15, to prevent the opening of tight junctions
Implementation Method 2
Mammalian epithelia contain structures referred to as zonula occludens (ZO) also referred to as tight junctions (TJs). These structures regulate the passage of materials through the epithelia by controlling access to the space between the epithelial cells (the paracellular pathway).
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides materials and methods to diagnose asthma. In some embodiments, the present invention provides a method of diagnosing asthma by measuring the zonulin level of a subject. The present invention also provides methods and compositions for treating asthma that comprise one or more zonulin antagonist.